CD40配體(CD40L)重組蛋白
Recombinant Cluster Of Differentiation 40 Ligand (CD40L)
CD154; TRAP; HIGM1; IGM; IMD3; TBAM; T-BAM; TNFSF5; Gp39; TNF Superfamily Member 5; Hyper-IgM Syndrome; TNF-Related Activation Protein; T-Cell B-Cell Activating Molecule
- 編號URPA119Hu02
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位分泌
- 預(yù)測分子量23.5kDa
- 實(shí)際分子量26kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Arg48~Pro244 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)7.2
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 420 ¥ 1050 ¥ 2100 ¥ 6300 ¥ 15750
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure . Gene Sequencing (extract)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA119Hu02 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA119Hu04 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA119Hu01 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA119Hu03 | CD40配體(CD40L)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA119Hu02 | CD40配體(CD40L)多克隆抗體 | WB |
| UPAA119Hu03 | CD40配體(CD40L)多克隆抗體 | IHC; ICC/IF |
| UPAA119Hu01 | CD40配體(CD40L)多克隆抗體 | WB; IHC; ICC; IP. |
| ULAA119Hu71 | CD40配體(CD40L)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| ULAA119Hu81 | CD40配體(CD40L)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| UMAA119Hu21 | CD40配體(CD40L)單克隆抗體 | IHC |
| UMAA119Hu23 | CD40配體(CD40L)單克隆抗體 | WB |
| UMAA119Hu22 | CD40配體(CD40L)單克隆抗體 | IHC; ICC/IF |
| UMAA119Hu25 | CD40配體(CD40L)單克隆抗體 | IHC |
| UMAA119Hu24 | CD40配體(CD40L)單克隆抗體 | IHC; ICC/IF |
| URAA119Hu21 | CD40配體(CD40L)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| URAA119Hu22 | CD40配體(CD40L)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| USEA119Hu | CD40配體(CD40L)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA119Hu | CD40配體(CD40L)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation [PubMed: 22899170] |
| Molecules | The Protective Effects of Alisol A 24-Acetate from Alisma canaliculatum on Ovariectomy Induced Bone Loss in Vivo [Pubmed:26760992] |
| Journal of Neuroinflammation | Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. [pubmed:28114998] |
| BMC Nephrology | Renal effects of metallothionein induction by zinc in vitro and in vivo [pubmed:28302075] |
| Toxicology and Applied Pharmacology | Effects of diisononyl phthalate on osteopenia in intact mice [pubmed:28893586] |
| INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation [Pubmed: 30857843] |
| Available at SSRN 3335365? | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers [] |
| Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation [] |
| journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers [Pubmed: 32812629] |
| Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices [Pubmed: 31838449] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
| Persistently higher serum sCD40L levels are associated with mortality in septic patients [] | |
| Journal of Orthopaedic Translation | Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-|êB and MAPK activation [33981577] |
| Bioactive Materials | Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy [34820587] |
留言咨詢
